Glaukos Corp

GKOS

Company Profile

  • Business description

    Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

  • Contact

    One Glaukos Way
    Aliso ViejoCA92656
    USA

    T: +1 949 367-9600

    E: [email protected]

    https://www.glaukos.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    1,094

Stocks News & Analysis

stocks

The 5 best US dividend aristocrats to watch in 2026

How to avoid the dividend aristocrat trap.
stocks

Chart of the Week: Is CSL finally turning the ship around?

The beaten down healthcare giant remains cheap on turnaround potential.
stocks

ASX top pick remains cheap with narrowing brand focus

Shares remain cheap for ASX winemaker as the company narrows focus on high margin brands.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,843.9078.400.89%
CAC 408,161.8341.60-0.51%
DAX 4024,195.31237.75-0.97%
Dow JONES (US)49,918.78953.33-1.87%
FTSE 10010,254.8127.480.27%
HKSE24,141.13266.83-1.09%
NASDAQ25,169.50509.32-1.98%
Nikkei 22564,056.44122.83-0.19%
NZX 50 Index13,202.1651.49-0.39%
S&P 5007,266.99119.66-1.62%
S&P/ASX 2008,642.5079.000.92%
SSE Composite Index3,978.5314.69-0.37%

Market Movers